TGR-1202

DRUG9 trials

Conditions

B-cell Non Hodgkin LymphomaCLLChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaColorectal CancerEsophageal CancerFollicular LymphomaGastric Cancer

Phase 1

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

CompletedNCT01767766

TG Therapeutics, Inc.Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma +1

Start: 2013-01-07End: 2018-02-28Updated: 2021-08-23

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

CompletedNCT02268851

Dana-Farber Cancer InstituteChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma

Start: 2014-11-30End: 2022-10-31Updated: 2024-11-15

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

CompletedNCT02493530

Vanderbilt-Ingram Cancer CenterMyelofibrosis, Polycythemia Vera

Start: 2015-07-31End: 2024-05-31Updated: 2024-06-27

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

CompletedNCT02574663

TG Therapeutics, Inc.Colorectal Cancer, Esophageal Cancer, Gastric Cancer +3

Start: 2015-09-11End: 2018-08-31Updated: 2019-10-02

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

TerminatedNCT02867618

Columbia UniversityHodgkin Disease, Lymphoma, Non-hodgkin

Start: 2016-10-16End: 2020-06-30Updated: 2021-07-16

Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL

Active, not recruitingNCT03283137

University of ChicagoB-cell Non Hodgkin Lymphoma, CLL

Start: 2018-01-23End: 2027-12-31Updated: 2025-02-07

Phase 2

TGR1202 in Relapsed and Refractory Follicular Lymphoma

TerminatedNCT03178201

Columbia UniversityFollicular Lymphoma

Start: 2017-08-20End: 2020-06-30Updated: 2021-07-16

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

TerminatedNCT03207256

TG Therapeutics, Inc.Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma

Start: 2017-08-09End: 2022-06-24Updated: 2022-07-21

Phase 3

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

TerminatedNCT02612311

TG Therapeutics, Inc.Chronic Lymphocytic Leukemia

Start: 2015-11-19End: 2023-02-22Updated: 2024-12-13

Blood2021-11-0510 citations

Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Blood2021-11-052 citations

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

Blood2020-11-0554 citations

Antibodies to watch in 2020.

2020-01-01328 citations

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

2018-12-1491 citations

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.

2018-02-20145 citations

Long-term follow-up of the PI3Kδ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.

Journal of Clinical Oncology2016-05-2020 citations

Activity of TGR-1202, a novel once-daily PI3Kδ inhibitor, in patients with relapsed or refractory hematologic malignancies.

Journal of Clinical Oncology2014-05-2015 citations

TGR-1202

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers